Loading clinical trials...

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma

NCT07475780•M.D. Anderson Cancer Center

Summary

The study will be an effectiveness study. The study will include enrollment of a total of 20 patients with at least one PC lesion for ultrasound guided RFA to PC recurrence in the neck to assess the effectiveness in reducing patient's hypercalcemia. Patients will have surgically proven PC from prior parathyroidectomy and suspicious PC visible on ultrasound and request for treatment for uncontrolled hypercalcemia (Figure 1).

Detailed Description

Primary Objective: • Evaluate treatment response of RFA of recurrent PC by means of longitudinal monitoring patient serum calcium level and PTH. Secondary Objectives: * Evaluate the sonographic features of the recurrent PC induced by RFA. * Evaluation of procedure-related complications * Disease free survival until recurrence of hypercalcemia

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient is older than 18 years, is not a surgical candidate or refuses to have surgery.
•2. Patient is medically fit to undergo local anesthesia with or without conscious sedation.
•3. Patient is able to understand and give consent to participation in the study.
•4. Confirmed parathyroid carcinoma by prior surgery and histopathology.
•5. Presence of local recurrence or implant in the neck visible on ultrasound.
•6. Distant oligometastasis visible on ultrasound.
•7. Solid nodule without macrocalcification or internal cystic degeneration
•8. Patient who is off of Cinacalcet
•9. Entirety of the selected nodule is visible on ultrasound without significant extension posterior to trachea or mediastinal component (ie Type A, E, or high F).
•10. Selected nodule is amenable to medial or lateral approach.
+3 more criteria

Exclusion Criteria

•Candidates will be ineligible for enrollment in the study if any of the following conditions apply:
•1. Patients with cardiac arrhythmia and/or implanted cardiac device
•2. Surgically naïve parathyroid lesions, parathyroid adenoma or atypical parathyroid tumor.
•3. Pregnancy
•4. Allergies to medications for anesthesia.
•5. Cystic nodules (\< 70% solid components)
•6. Calcified nodules
•7. Targeted nodule within 0.5 cm from the major vessels, vagus nerve, brachial plexus, and recurrent laryngeal nerve.
•8. Patients with contralateral vocal cord paralysis.
•9. Uncorrectable coagulopathy with PTT\>1.5 X ULN or INR \>1.5 or platelet count \<100,000 per mm3

Locations (1)

UT MD Anderson

Houston, Texas, United States

Key Dates

Start Date

August 31, 2026

Primary Completion Date

April 30, 2029

Completion Date

April 30, 2031

Last Updated

March 17, 2026

Enrollment

ESTIMATED participants

Conditions

Recurrent Parathyroid Carcinoma

Interventions

Ultrasound-guided RFA

DEVICE

Contacts

Thinh Vu, MD

CONTACT

(281) 415-2061 thinh.vu@mdanderson.org